Related Experiment Videos
Familial Hypercholesterolemia
1Cardiovascular Genetics Research, University of Utah School of Medicine, 410 Chipeta Way, Room 167, Salt Lake City, UT 84108, USA. paul@ucvg.med.utah.edu
Insights
Familial hypercholesterolemia (FH) is a common genetic condition causing high LDL cholesterol. Early diagnosis and aggressive combination drug therapy, including statins, can help manage FH and regress coronary lesions.
Area of Science:
- Cardiology
- Genetics
- Metabolic Disorders
Background:
- Familial hypercholesterolemia (FH) is a prevalent, severe genetic disorder characterized by elevated plasma low-density lipoprotein (LDL) cholesterol.
- FH remains under-recognized and under-treated, despite the availability of effective lipid-lowering therapies.
- The MEDPED (Make Early Diagnoses, Prevent Early Deaths) organization was established globally to identify and support individuals with FH.
Purpose of the Study:
- To highlight the challenges in diagnosing and treating FH.
- To emphasize the need for aggressive therapeutic strategies in FH management.
- To present evidence for the efficacy of combination therapy in FH patients.
Main Methods:
- Review of existing literature on FH diagnosis and treatment.
- Description of the MEDPED initiative for global FH identification.
- Analysis of treatment outcomes in FH patients receiving various lipid-lowering medications.
Main Results:
- Some FH patients achieve LDL goals with statin monotherapy.
- Many FH patients require combination therapy (statin, bile acid sequestrant, niacin) to reach LDL targets.
- Aggressive treatment led to regression of coronary lesions in FH patients.
Conclusions:
- FH is a significant public health issue requiring improved detection and management.
- Combination drug therapy is often necessary for effective LDL cholesterol reduction in FH.
- Intensive lipid-lowering treatment can improve cardiovascular outcomes in FH by regressing coronary artery disease.
Abstract:
Heterozygous familial hypercholesterolemia is a common, severe form of elevated plasma, low-density lipoprotein (LDL) cholesterol. Familial hypercholesterolemia is under-recognized and under-treated despite well-known benefits from available lipid-lowering medications. To help address these problems, the humanitarian MEDPED (Make Early Diagnoses, Prevent Early Deaths) organization was developed as a means to find and help persons with familial hypercholesterolemia all over the world. Although some patients with familial hypercholesterolemia can be treated adequately with a statin alone, many require aggressive treatment with a combination of drugs, including a statin, bile acid sequestrant, and niacin to reach LDL goals. Such treatment has resulted in regression of angiographically monitored coronary lesions in patients with familial hypercholesterolemia.